Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
News and updates on ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) focus on its progress as a clinical stage oncology company developing therapies that address mechanisms of therapeutic resistance in cancer. ORIC regularly reports clinical data, operational milestones, and financial updates that are relevant to investors and observers following the ORIC stock and its development programs.
Recent news highlights include Phase 1b data for ORIC-944 (also referred to as rinzimetostat) in metastatic castration-resistant prostate cancer, where the company has discussed PSA responses, circulating tumor DNA reductions, and a safety profile described as compatible with long-term dosing when combined with androgen receptor inhibitors. ORIC also provides updates on preclinical findings for ORIC-944 in castration-sensitive prostate cancer models and KRAS G12C-mutant NSCLC and colorectal cancer models.
For enozertinib (ORIC-114), ORIC’s news flow includes late-breaking oral and poster presentations at major scientific meetings such as the ESMO Asia Congress. The company reports systemic and CNS activity in non-small cell lung cancer patients with EGFR exon 20, EGFR atypical (including PACC), and HER2 exon 20 mutations, including in patients with active brain metastases. These articles often detail objective response rates, disease control rates, intracranial responses, and safety observations from Phase 1b cohorts.
Corporate news items cover participation in healthcare conferences, strategic pipeline prioritization to focus on ORIC-944 and enozertinib, leadership appointments such as the creation of a Chief Technical Officer role, and capital raises via private placements and at-the-market programs. Financial press releases summarize quarterly results, research and development spending, and the company’s cash and investment position.
This news page aggregates ORIC’s press releases and related disclosures so readers can follow clinical trial readouts, program updates, corporate developments, and other material events affecting ORIC Pharmaceuticals and the ORIC ticker over time.
ORIC (Nasdaq: ORIC) announced a peer-reviewed publication in Cancer Research describing the discovery and preclinical development of enozertinib, an oral, irreversible EGFR inhibitor designed for EGFR exon 20 and atypical mutations. The paper reports enozertinib’s exquisite kinome selectivity, strong potency, and brain penetration, with anti-tumor activity in intracranial lung cancer models. The publication includes a patient vignette reporting a sustained systemic and CNS complete response in an NSCLC patient with an EGFR exon 20 insertion. ORIC said it will present multiple clinical datasets in December 2025 (ESMO Asia 2025) and additional 1L combination data in mid-2026.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced management will participate in three investor conferences in November 2025: a fireside chat at Guggenheim’s 2nd Annual Healthcare Innovation Conference on Nov 11, 2025 at 1:30 p.m. ET, one-on-one meetings at Stifel 2025 Healthcare Conference on Nov 12, 2025, and a fireside chat at Jefferies London Healthcare Conference on Nov 19, 2025 at 2:30 p.m. GMT. Management will also hold one-on-one meetings at the Guggenheim and Jefferies events.
Webcasts of the fireside chats will be available via the company’s investor website and replays will remain available for 90 days following each event.
ORIC Pharmaceuticals (Nasdaq: ORIC) presented preclinical data on ORIC-944, an allosteric PRC2 inhibitor targeting EED, at the 2025 EORTC-NCI-AACR conference on October 27, 2025. Key findings show ORIC-944 combined with androgen receptor (AR) inhibitors delayed relapse and improved survival in castration-sensitive prostate cancer preclinical models by restricting cellular plasticity and lineage adaptation. In KRAS G12C models, ORIC-944 plus the KRAS inhibitor adagrasib regressed 100% of tumors in NSCLC xenografts, prevented tumor relapse and extended progression-free survival. Transcriptional and chromatin changes consistent with PRC2 inhibition were reported across tumor types.
All results reported are preclinical and described as supporting ORIC-944's potential as a best-in-class PRC2 inhibitor.
ORIC Pharmaceuticals (Nasdaq:ORIC), a clinical stage oncology company, has granted equity-based inducement awards to a new non-executive employee who joined in August 2025. The grants include 292,500 non-qualified stock options and 79,000 restricted stock units.
The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The restricted stock units will vest in three equal annual installments. These grants were made under the company's 2022 Inducement Equity Incentive Plan and approved by the Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company, has announced its participation in five major investor conferences in September 2025. The company will engage in fireside chats and one-on-one meetings at the Citi Biopharma Back to School Summit, Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, and Baird Global Healthcare Conference.
Webcasts of the fireside chat discussions will be accessible through ORIC's investor relations website, with replays available for 90 days after each event.
ORIC Pharmaceuticals (Nasdaq: ORIC) has appointed Kevin Brodbeck, PhD as its first Chief Technical Officer (CTO), strengthening its leadership team ahead of potential Phase 3 trials in 2026. Dr. Brodbeck brings over 25 years of experience in technical operations, quality assurance, and CMC activities.
The strategic appointment comes as ORIC prepares for late-stage development of two key programs: ORIC-944 and enozertinib (ORIC-114). Dr. Brodbeck's previous roles include Chief Technical and Development Operations Officer at Deciphera Pharmaceuticals and SVP of Technical Operations at Nektar Therapeutics, where he led various development programs and managed global CMC operations.
ORIC Pharmaceuticals (Nasdaq: ORIC) reported Q2 2025 financial results and operational updates, highlighting significant progress in its clinical programs. The company secured $244 million in financing, including a $125 million private placement and $119 million from ATM issuances, extending its cash runway into 2H 2028.
Key highlights include promising Phase 1b trial results for ORIC-944 in prostate cancer treatment, showing a 59% PSA50 response rate and 24% PSA90 response rate. The company is advancing both ORIC-944 and ORIC-114 (enozertinib) towards potential Phase 3 trials in 2026. As part of a strategic restructuring, ORIC is reducing its discovery research investment, resulting in a 20% workforce reduction.
ORIC Pharmaceuticals (Nasdaq:ORIC), a clinical stage oncology company, has announced the granting of inducement equity awards to two new non-executive employees. The grants, approved under Nasdaq Rule 5635(c)(4), include 35,000 non-qualified stock options and 5,800 restricted stock units.
The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The restricted stock units will vest in three equal annual installments. These grants were made through the company's 2022 Inducement Equity Incentive Plan and were approved by ORIC's Compensation Committee.
ORIC Pharmaceuticals (Nasdaq:ORIC), a clinical stage oncology company, has granted equity inducement awards to a new non-executive employee. The grants, approved on July 1, 2025, include 9,000 non-qualified stock options and 1,600 restricted stock units.
The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The restricted stock units will vest in three equal annual installments. These grants were made under the company's 2022 Inducement Equity Incentive Plan and approved by the Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).